Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Byung-Hyun | - |
dc.contributor.author | Kang, Ka-Won | - |
dc.contributor.author | Jeon, Min Ji | - |
dc.contributor.author | Yu, Eun Sang | - |
dc.contributor.author | Kim, Dae Sik | - |
dc.contributor.author | Lee, Se Ryeon | - |
dc.contributor.author | Sung, Hwa Jung | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.date.accessioned | 2022-02-27T12:41:07Z | - |
dc.date.available | 2022-02-27T12:41:07Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-07-14 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137135 | - |
dc.description.abstract | Background Cereblon (CRBN) is a direct target of immunomodulatory drugs (IMiDs) and is known to be sensitive and responsive to IMiD therapy. We evaluated CRBN expression in bone marrow plasma cells and analyzed whether CRBN expression was associated with multiple myeloma prognosis. Lastly, we developed a nomogram model for predicting high CRBN expression based on clinically significant blood markers. & nbsp; Methods We evaluated 143 multiple myeloma patients (internal dataset) who underwent bone marrow examinations. For evaluating the prognostic ability of the nomogram model, two external cohorts (235 patients in external dataset 1 and 156 patients in external dataset 2) were analyzed. The expression of CRBN in bone marrow aspirate samples was evaluated using immunohistochemistry. High CRBN expression was defined as the study-defined H-score >= 6. & nbsp; Results In the high CRBN group, the median progression-free survival (PFS) and overall survival (OS) of patients receiving the IMiD-based therapy and non-IMiD therapy were 29 and 10 months for PFS, and NR (not reached) and 54 months for OS, respectively. IMiD-based therapy was significantly associated with better PFS and OS outcomes. High CRBN expression was independently predicted by female sex, high serum free-light chain (FLC) ratio, higher serum M-protein level, and higher beta 2-microglobulin level. Based on these results, we constructed a new nomogram model to predict high CRBN expression and the effectiveness of IMiD therapy in multiple myeloma. & nbsp; Conclusion This nomogram could improve the prognostic evaluation of myeloma patients exhibiting high CRBN expression treated with IMiD therapy and might help provide personalized treatment strategies to clinicians. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.subject | LENALIDOMIDE | - |
dc.subject | DEXAMETHASONE | - |
dc.subject | THALIDOMIDE | - |
dc.subject | SURVIVAL | - |
dc.subject | SUPERIOR | - |
dc.title | Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Dae Sik | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.identifier.doi | 10.3389/fonc.2021.687361 | - |
dc.identifier.scopusid | 2-s2.0-85111556510 | - |
dc.identifier.wosid | 000679033800001 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, v.11 | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.citation.title | FRONTIERS IN ONCOLOGY | - |
dc.citation.volume | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | SUPERIOR | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THALIDOMIDE | - |
dc.subject.keywordAuthor | cereblon | - |
dc.subject.keywordAuthor | immunomodulatory therapy | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordAuthor | nomograms | - |
dc.subject.keywordAuthor | prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.